aTyr Pharma reports Q3 2023 cash of $105.6M; Phase 3 sarcoidosis study enrollment to complete early Q2 2024

aTYR PHARMA INC

2023-Q3 EPS reported -$0.69 revenue$353,000

Cash, cash equivalents and investments totaled $105.6M as of September 30, 2023.
Phase 3 EFZO-FIT study in pulmonary sarcoidosis expects enrollment completion early Q2 2024; positive DSMB safety review.
Phase 2 EFZO-CONNECT study in systemic sclerosis-ILD dosed first patient.
R&D expenses were $10.3M, G&A $2.6M, collaboration revenue $0.4M from Kyorin agreement.
Updated cash runway guidance: sufficient through BLA filing for efzofitimod in sarcoidosis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

aTYR PHARMA INC updated its third quarter of 2023 guidance (reaffirmed).

Period: third quarter of 2023
Guidance: reaffirmed
Result: reported results

Exact text from the filing

On November 9, 2023, aTyr Pharma, Inc. issued a press release announcing financial results for the quarter ended September 30, 2023.

View on SEC.gov

19 earnings releases filed in the last 30 days. Browse all earnings releases →

aTYR PHARMA INC filing history →

Source: SEC EDGAR

accession 0000950170-23-062020

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.